Nova Eye Sales Growth Accelerates As Quarterly Cash Flow Turns Positive
Nova Eye Medical reported quarterly sales up 30% year on year, with trailing 12-month sales growth accelerating from 26% to 30%. It generated positive operating cash flow, compared with an outflow in the prior-year quarter, and reported positive EBITDA for a second consecutive reporting period. FY27 sales and positive EBITDA guidance was confirmed.
Closing price · 2026-10-27: $0.160 · +6.67%